- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03017482
Clinical Startup of the 670G Closed Loop Insulin Delivery System (670Gstartup)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
3.1 Initial Procedures After reviewing the patient's interest and eligibility, the investigators will obtain informed consent and assent as appropriate. The investigators will start the clinical process for starting an insulin infusion pump. This typically involves attending a pre-pump class (for those patients naïve to insulin pump therapy) and starting the process to obtain insurance coverage for the 670G system.
The investigators plan to track the insurance approval process, typically the number of calls and faxes required, as well as the result - approved vs not approved.
3.2 Pump Run-in (for those patients new to insulin infusion pumps) For patients who are insulin pump naïve the investigators will start on 670G insulin pump without the glucose sensor activation as per our existing clinical protocol. This may occur at a group visit.
3.3 Initial Visit
During at an initial visit, the following procedures will be performed:
- A clinically obtained HbA1c assessment, typically done via fingerstick and DCA2000 (but any equivalent NGSP-certified point-of-care or laboratory based measurement within 2 weeks prior to enrollment acceptable)
Collection of medical history information including
- Demographics (date of birth, gender, race and ethnicity), diabetes history, medical history, concomitant medications
- Collect data for diabetes devices (eg meters, sensors, pumps)
- Brief clinical physical exam including vital signs and skin assessment
- CareLink account creation and sharing of access if this is not already done At this visit, patients will be taught how to insert and use the system glucose sensor.
3.3.1 Initial Week on the 670G System During the following week, the system (with both pump and sensor active) will be active with the PLGS on.
3.4 System Start Visit After the initial PLGS week, patients will be taught, perhaps as a group, the closed loop system and the system activated. (Note: multiple days of system data are required using the pump and sensor prior to the 670G system being capable of delivering additional insulin for hyperglycemia. Therefore, this stage of the start-up is a function of the system requirements.)
3.5 Weekly CareLink Download and Calls For each of the next four weeks, the patient/family will upload data into the CareLink system and the data will be reviewed by a member of the clinical team. Adjustments to system settings will be suggested to the family as clinically appropriate.
3.6 Routine 3, 6, 9 and 12 Month Clinical visits At a routine clinical visits the investigators will obtain an interval medical history, physical examination, collect and review of diabetes management data from all diabetes devices with an eye towards improving glycemic control. The investigators will collect adverse event information regarding severe hypoglycemia and diabetic ketoacidosis. Patients will be advised of suggested changes in pump settings
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.
- Clinically planning to and be able to start the Medtronic 670G closed loop system
- Age greater than 7.00 years at the initiation of the 670G system
- Total daily insulin use of great than 8.0 units per day over a 1 week period
- Willing and able (access to internet from home) to download information into the Medtronic CareLink software
Exclusion Criteria:
- 1) Current or planned pregnancy (for the next 12 months)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
percent of time patients are on the closed loop system
Time Frame: 6 month
|
percent of time patients are on the closed loop system at 6 months after start of closed loop activation with a goal of >70%.
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent time in range
Time Frame: 6 months
|
Percent time in range (70 to 180 mg/dL) "Week 1 before closed loop but with predictive low glucose suspend (PLGS)" vs "Week 24 on full closed loop control."
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severe Hypoglycemia
Time Frame: 12 months
|
Number of severe hypoglycemic events in 12 months on closed loop compared with the up to 12 months before by history before closed loop control
|
12 months
|
Diabetic Ketoacidosis
Time Frame: 12 months
|
Number of diabetic ketoacidosis (DKA) events in 12 months on closed loop compared with the up to 12 months before by history before closed loop control
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Darrell M Wilson, MD, Stanford University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 670Gstartup
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Medtronic 670G
-
Rabin Medical CenterMedtronic; GIFCompleted
-
Universitaire Ziekenhuizen KU LeuvenRecruitingDiabetes Mellitus, Type 1Belgium
-
Atlanta Diabetes AssociatesMedtronicRecruiting
-
Nemours Children's ClinicWashington University School of Medicine; Yale University; University of Iowa; National... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States
-
HealthPartners InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Yale... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States, Germany, Slovenia, Israel
-
Texas Diabetes & Endocrinology, P.A.CompletedType 1 Diabetes MellitusUnited States
-
Hamad Medical CorporationSidra MedicineUnknown
-
Kinderkrankenhaus auf der BultCompletedDrug Therapy | Patient CareGermany
-
Jesús Moreno FernándezUniversity of Castilla-La ManchaCompleted
-
Boston Children's HospitalCompletedType 1 Diabetes | Biomedical TechnologyUnited States